首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   35225篇
  免费   3091篇
  国内免费   53篇
耳鼻咽喉   382篇
儿科学   1342篇
妇产科学   1010篇
基础医学   4801篇
口腔科学   780篇
临床医学   4988篇
内科学   6248篇
皮肤病学   495篇
神经病学   3041篇
特种医学   999篇
外国民族医学   1篇
外科学   3457篇
综合类   1063篇
一般理论   46篇
预防医学   4477篇
眼科学   589篇
药学   2382篇
中国医学   31篇
肿瘤学   2237篇
  2022年   219篇
  2021年   588篇
  2020年   378篇
  2019年   593篇
  2018年   659篇
  2017年   498篇
  2016年   593篇
  2015年   689篇
  2014年   910篇
  2013年   1413篇
  2012年   1943篇
  2011年   2036篇
  2010年   1101篇
  2009年   992篇
  2008年   1862篇
  2007年   1986篇
  2006年   1967篇
  2005年   1848篇
  2004年   1838篇
  2003年   1718篇
  2002年   1676篇
  2001年   750篇
  2000年   748篇
  1999年   667篇
  1998年   457篇
  1997年   383篇
  1996年   393篇
  1995年   373篇
  1994年   314篇
  1993年   330篇
  1992年   528篇
  1991年   498篇
  1990年   503篇
  1989年   512篇
  1988年   503篇
  1987年   388篇
  1986年   419篇
  1985年   452篇
  1984年   335篇
  1983年   287篇
  1982年   233篇
  1981年   249篇
  1980年   207篇
  1979年   274篇
  1978年   236篇
  1977年   250篇
  1976年   218篇
  1974年   211篇
  1973年   203篇
  1972年   190篇
排序方式: 共有10000条查询结果,搜索用时 468 毫秒
1.
2.
ABSTRACT

Measuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised.  相似文献   
3.
ABSTRACT

This work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated.  相似文献   
4.
5.
6.

Background

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods

Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results

Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions

No safety concerns arose, supporting the favorable benefit-risk profile of RZV.  相似文献   
7.
8.
9.
Annals of Surgical Oncology - The role of sentinel lymph node biopsy (SLNB) when ductal carcinoma in situ with microinvasion (DCISM) is identified on core biopsy is unclear. Our aim was to assess...  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号